Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17625

    +

    P2.03a-069 - Effectivenes of Adjuvant Carboplatin-Based Chemotherapy Compared to Cisplatin in Resected Non-Small Cell Lung Cancer (ID 3808)

    14:30 - 14:30  |  Author(s): J. Cote
    • Abstract
    • Slides

    Background:
    Cisplatin and vinorelbine given intravenously is a well-established adjuvant chemotherapy regimen after surgery for early NSCLC. However, few validated alternative exist when cisplatin is not indicated or tolerated. Carboplatin is frequently used in this setting. We evaluated the 5 years overall survival (OS), progression-free survival (PFS) and toxicity in patients treated for stage IB to IIIB resected NSCLC receiving adjuvant carboplatin based chemotherapy compared to cisplatin in association with vinorelbine.
    
    Methods:
    Single-center retrospective study of patients having received adjuvant chemotherapy between January 2004 and December 2013 at the oncology clinic at Institut de Cardiologie et de Pneumologie de Québec (Canada). Three sub-groups were studied: cisplatin / vinorelbine (CISV), carboplatin / vinorelbine (CBV) and the substitution of cisplatin /vinorelbine for carboplatin /vinorelbine during treatment.
    
    Results:
    A total of 127 patients were included in this study. The overall survival (OS) at 5 years and the median progression-free survival (PFS) did not differ significantly between groups. The 5 years OS is respectively 66 %, 55 % and 70 % (p = 0, 95). The PFS is respectively 50,4 and 57,3 months for the CISV and CISV/CBV groups and was not achieved for the CBV group (p = 0,80). No differences were noted between groups concerning grade 3 or 4 hematologic toxicity.
    
    Conclusion:
    The effectiveness and hematologic toxicity are comparable between cisplatin and carboplatin in the adjuvant treatment of resected non-small cell lung cancer. The results obtained corroborate the practice used at our oncology clinic. Nevertheless, more prospective studies would be needed to confirm these results.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.